Deerfield Management

Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.

Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Springtide Child Development, Inc. provides child development services. It offers personalized and holistic treatment plans. The company provides Applied behavior analysis therapy for autism, speech therapy, occupational therapy, physical therapy, language acquisition, social skills, school readiness, and functional living skill development services. Springtide Child Development, Inc. was incorporated in 2018 and is based in Trumbull, Connecticut.

Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

Arvinas is a pharmaceutical company that focuses on developing novel therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare diseases. Its proprietary approach is the targeting of disease-causing proteins for degradation thus eliminating them from the body. The company was founded in 2013 and is headquartered in Connecticut, United States.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company specializing in the discovery, development, and commercialization of anti-infective therapies targeting bacterial infections. The company offers several products, including Baxdela, Vabomere, Orbactiv, and Minocin, which address various acute bacterial skin infections and gram-negative infections. Recognizing the urgent need for new antibiotics to combat drug-resistant infections, Melinta is advancing delafloxacin, currently in Phase 3 development for treating acute bacterial skin and skin structure infections. The company also focuses on developing innovative antibiotics aimed at overcoming resistant pathogens associated with serious hospital infections. Established in 2000, Melinta Therapeutics is headquartered in Morristown, New Jersey, and operates with support from strategic partners in the healthcare sector.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company focuses on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK, currently undergoing Phase I clinical trials for advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as an antibody-drug conjugate known as KIT-ADC for oncology applications. The company also engages in various research programs targeting RTKs, building on foundational discoveries made in collaboration with Dr. Joseph Schlessinger's laboratory at Yale University, which elucidate the molecular mechanisms linked to RTK activation and oncogenic mutations.